What it is
LL-37 is a host-defense peptide protocol used in TWW's immunity protocols. In simple terms, it is meant to support innate immunity and antimicrobial defense. Some peptides act like small biological messages, while others support peptide-adjacent pathways such as mitochondrial function, redox balance, or hormone signaling.
LL-37 is a naturally occurring human antimicrobial peptide produced from the cathelicidin protein. It is found in barrier tissues such as skin, airway, gut lining, and immune-cell environments.
The practical goal is to understand what signal this peptide is trying to send, then decide whether that signal matches the person's goals, labs, symptoms, and overall health picture.
What it may help with
The larger idea is immune resilience. These protocols are considered when the goal is to support immune coordination, barrier defense, surveillance, and recovery rather than simply stimulating immunity. For LL-37, the suspected benefits come from the way this pathway appears to influence innate immunity and antimicrobial defense. These are not guaranteed outcomes, but they explain why the peptide is considered in certain wellness protocols.
What it’s used for
In peptide protocols, this is usually considered as part of a broader plan rather than as a stand-alone “magic bullet.” At TWW, that means matching the peptide to the clinical pattern, the goal of care, and the other pieces of the plan such as nutrition, training, sleep, lab review, or recovery work.
- Immune-resilience discussions when barrier function and recurrent infectious susceptibility are part of the history.
- Gut/skin/respiratory barrier-support frameworks.
- Advanced protocols where risks, immune status, and medication interactions are reviewed.